Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1982 1
1984 1
1985 3
1986 1
1988 1
1989 1
1990 3
1991 1
1995 1
1996 1
1998 2
1999 2
2000 2
2002 4
2003 2
2004 4
2005 3
2006 5
2007 7
2008 8
2009 2
2010 4
2011 1
2012 3
2013 3
2014 2
2015 4
2016 1
2018 2
2019 3
2020 2
2022 2
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).
Quinlivan R, Martinuzzi A, Schoser B. Quinlivan R, et al. Cochrane Database Syst Rev. 2014 Nov 12;2014(11):CD003458. doi: 10.1002/14651858.CD003458.pub5. Cochrane Database Syst Rev. 2014. PMID: 25391139 Free PMC article. Review.
Background McArdle disease (Glycogen Storage Disease type V) is caused by an absence of muscle phosphorylase leading to exercise intolerance,myoglobinuria rhabdomyolysis and acute renal failure. ...The included studies involved a total of 85 par …
Background McArdle disease (Glycogen Storage Disease type V) is caused by an absence of muscle phosphoryl …
Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).
Quinlivan R, Martinuzzi A, Schoser B. Quinlivan R, et al. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD003458. doi: 10.1002/14651858.CD003458.pub4. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2014 Nov 12;(11):CD003458. doi: 10.1002/14651858.CD003458.pub5. PMID: 21154353 Updated. Review.
BACKGROUND: McArdle disease (Glycogen Storage Disease type V) is caused by an absence of muscle phosphorylase leading to exercise intolerance, myoglobinuria rhabdomyolysis and acute renal failure. ...SEARCH STRATEGY: We searched the Cochrane Neu …
BACKGROUND: McArdle disease (Glycogen Storage Disease type V) is caused by an absence of muscle phosphory …
Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).
Quinlivan R, Beynon RJ, Martinuzzi A. Quinlivan R, et al. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD003458. doi: 10.1002/14651858.CD003458.pub3. Cochrane Database Syst Rev. 2008. Update in: Cochrane Database Syst Rev. 2010 Dec 08;(12):CD003458. doi: 10.1002/14651858.CD003458.pub4. PMID: 18425888 Updated. Review.
BACKGROUND: McArdle disease (Glycogen Storage Disease type V) is caused by the absence of the glycolytic enzyme, muscle phosphorylase. ...SEARCH STRATEGY: We updated the review by searching the Cochrane Neuromuscular Disease Group Trials Registe …
BACKGROUND: McArdle disease (Glycogen Storage Disease type V) is caused by the absence of the glycolytic …
Pharmacological and nutritional treatment for McArdle's disease (Glycogen Storage Disease type V).
Quinlivan R, Beynon RJ. Quinlivan R, et al. Cochrane Database Syst Rev. 2004;(3):CD003458. doi: 10.1002/14651858.CD003458.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2008 Apr 16;(2):CD003458. doi: 10.1002/14651858.CD003458.pub3. PMID: 15266486 Updated. Review.
BACKGROUND: McArdle's disease (Glycogen Storage Disease type V) is caused by the absence of the glycolytic enzyme, muscle phosphorylase. ...SEARCH STRATEGY: We searched the Cochrane Neuromuscular Disease Group register (searched December 2001 an …
BACKGROUND: McArdle's disease (Glycogen Storage Disease type V) is caused by the absence of the glycolyti …
Therapeutic options in other metabolic myopathies.
Vorgerd M. Vorgerd M. Neurotherapeutics. 2008 Oct;5(4):579-82. doi: 10.1016/j.nurt.2008.08.006. Neurotherapeutics. 2008. PMID: 19019309 Free PMC article. Review.
The current therapeutic options of glycogen and lipid storage myopathies include dietary treatments, excersise training, and pharmacological supplementations. Herein is a review of evidence from randomized controlled trials in McArdle disease (glycogen storage …
The current therapeutic options of glycogen and lipid storage myopathies include dietary treatments, excersise training, and pharmacological …
Physical training for McArdle disease.
Quinlivan R, Vissing J, Hilton-Jones D, Buckley J. Quinlivan R, et al. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD007931. doi: 10.1002/14651858.CD007931.pub2. Cochrane Database Syst Rev. 2011. PMID: 22161416 Review.
SEARCH METHODS: We searched the Cochrane Neuromuscular Disease Group Specialized Register (11 January 2011), CENTRAL (2010, Issue 4), MEDLINE (January 1966 to January 2011) and EMBASE (January 1980 to January 2011). SELECTION CRITERIA: All randomised and quasi-randomise …
SEARCH METHODS: We searched the Cochrane Neuromuscular Disease Group Specialized Register (11 January 2011), CENTRAL (2010, Issue 4), MEDLIN …
Creatine for treating muscle disorders.
Kley RA, Vorgerd M, Tarnopolsky MA. Kley RA, et al. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004760. doi: 10.1002/14651858.CD004760.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2011 Feb 16;(2):CD004760. doi: 10.1002/14651858.CD004760.pub3. PMID: 17253521 Updated. Review.
SELECTION CRITERIA: Types of studies: randomised or quasi-randomised controlled trials. TYPES OF PARTICIPANTS: people of all ages with hereditary muscle disease. ...One trial reported a significant increase in muscle pain during high-dose creatine treatment ( …
SELECTION CRITERIA: Types of studies: randomised or quasi-randomised controlled trials. TYPES OF PARTICIPANTS: people of all a …
Genetic predisposition to statin myopathy.
Vladutiu GD. Vladutiu GD. Curr Opin Rheumatol. 2008 Nov;20(6):648-55. doi: 10.1097/BOR.0b013e328314b7b4. Curr Opin Rheumatol. 2008. PMID: 18946323 Review.
Can hyperuricemia predict glycogen storage disease (McArdle's disease) in rheumatology practice? (Myogenic hyperuricemia).
Üsküdar Cansu D, Erdoğan B, Korkmaz C. Üsküdar Cansu D, et al. Clin Rheumatol. 2019 Oct;38(10):2941-2948. doi: 10.1007/s10067-019-04572-8. Epub 2019 May 1. Clin Rheumatol. 2019. PMID: 31044384 Review.
Gout disease is an inflammatory arthritis that arises due to the accumulation of monosodium urate crystals (MSU) around the joints and in tissues. Clinical manifestation of metabolic diseases leading to secondary hyperuricemia most predominantly occurs in the form of gouty …
Gout disease is an inflammatory arthritis that arises due to the accumulation of monosodium urate crystals (MSU) around the joints and in ti …
Metabolic myopathies: the challenge of new treatments.
Angelini C, Semplicini C. Angelini C, et al. Curr Opin Pharmacol. 2010 Jun;10(3):338-45. doi: 10.1016/j.coph.2010.02.006. Epub 2010 Mar 29. Curr Opin Pharmacol. 2010. PMID: 20356791 Review.
A well known hypolipidemic drug, bezafibrate, has been tested to stimulate expression of mutated gene for CPT 2, but it may represent a challenge for a series of other fatty acid mitochondrial disorders to restore the capacity for normal long-chain fatty oxidation in muscle. The …
A well known hypolipidemic drug, bezafibrate, has been tested to stimulate expression of mutated gene for CPT 2, but it may represent a chal …
87 results